Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioTissue begins skin substitute study:

This article was originally published in Clinica

Executive Summary

German tissue engineering firm BioTissue Technologies has begun an international, multicentre study of its skin cell substitute, BioSeed-S, designed to generate data to support the coverage of the product by health insurance bodies. Professor Wolfgang Vanscheidt, director of the Wound Biology Clinic in Hochenschwand, Germany, and president of the German Wound Healing Association, is heading the study. BioSeed-S is already being marketed globally under an exclusive marketing deal between Freiburg-based BioTissue Technologies and Baxter International.

You may also be interested in...



Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Advancing The Precision Mission At RSNA 2020

RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.

Highest European Court Rules CBD Is Not A Narcotic Drug

The European Court of Justice rules that CBD cannot be regarded as a narcotic as it is non-psychoactive and suggests that a French ban on the cannabinoid is contrary to EU law on the free movement of goods. Legal experts and industry hope the judgment will pave the way for a regulated European CBD market.

Topics

UsernamePublicRestriction

Register

OM005385

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel